keyword
https://read.qxmd.com/read/38499186/novel-perspectives-on-thrombopoietin-receptor-agonists-applications
#21
JOURNAL ARTICLE
Christos Stafylidis, Dimitra Vlachopoulou, Stavroula Syriopoulou, Sevastianos Chatzidavid, Nora-Athina Viniou
Second-generation thrombopoietin receptor agonists (TPO-RAs), romiplostim, eltrombopag, and avatrombopag, have been proved to be significant stimulators of megakaryopoiesis and, in the last decade, they have been incorporated in the treatment options against refractory immune thrombocytopenia in children and adults that do not respond to conventional therapy. Additionally, given their beneficial impact on hematopoiesis, they have successfully been applied in cases of non-immune thrombocytopenia, such as aplastic anemia, HCV-related thrombocytopenia, chronic liver disease, and most recently acute radiation syndrome...
March 18, 2024: Hämostaseologie
https://read.qxmd.com/read/38489521/imaging-based-non-invasive-liver-disease-assessment-for-staging-liver-fibrosis-in-chronic-liver-disease-a-systematic-review-supporting-the-aasld-practice-guideline
#22
JOURNAL ARTICLE
Andres Duarte-Rojo, Bachir Taouli, Daniel H Leung, Deborah Levine, Tarek Nayfeh, Bashar Hasan, Yahya Alsawaf, Samer Saadi, Abdul Mounaem Majzoub, Apostolos Manolopoulos, Samir Hafar, Ayca Dundar, M Hassan Murad, Don C Rockey, Mouaz Alsawas, Richard K Sterling
BACKGROUND AND AIMS: Transient elastography (TE), shear-wave elastography (SWE), and/or magnetic resonance elastography (MRE), each providing liver stiffness measurement (LSM), are the most studied imaging-based noninvasive liver disease assessment (NILDA) techniques. To support the American Association for the Study of Liver Diseases guidelines on NILDA, we summarized the evidence on the accuracy of these LSM methods to stage liver fibrosis (F). APPROACH AND RESULTS: A comprehensive search for studies assessing LSM by TE, SWE, or MRE for the identification of significant fibrosis (F2-4), advanced fibrosis (F3-4), or cirrhosis (F4), utilizing histopathology as standard of reference by liver disease etiology in adults or children from inception to April 2022 was performed...
March 15, 2024: Hepatology: Official Journal of the American Association for the Study of Liver Diseases
https://read.qxmd.com/read/38477384/measurement-practices-of-alanine-aminotransferase-in-children-temporal-changes-and-etiology-for-increased-values
#23
JOURNAL ARTICLE
Linnea Aitokari, Pauliina Hiltunen, Heini Huhtala, Kalle Kurppa, Laura Kivelä
Data on alanine aminotransferase (ALT) measurement practices and diagnoses associated with increased values are limited. We evaluated these issues by collecting ALT measurements from 1- to 16-year-old patients investigated in 1992-2018 in a tertiary center. Diagnoses were gathered in 2008-2018. Altogether 145,092 measurements from 28,118 children were taken 42% undergoing repeated testing. Testing increased from 21/1000 to 81/1000 children and the prevalence of elevated values fluctuated between 18% and 26%...
March 13, 2024: Journal of Pediatric Gastroenterology and Nutrition
https://read.qxmd.com/read/38476092/cdc-s-new-hepatitis-c-virus-testing-recommendations-for-perinatally-exposed-infants-and-children-a-step-towards-hepatitis-c-elimination
#24
JOURNAL ARTICLE
Lakshmi Panagiotakopoulos, Kathryn Miele, Emily J Cartwright, Saleem Kamili, Nathan Furukawa, Kate Woodworth, Van T Tong, Shin Y Kim, Carolyn Wester, Amy L Sandul
New U.S. Centers for Disease Control and Prevention (CDC) guidelines for hepatitis C virus (HCV) testing of perinatally exposed infants and children released in 2023 recommend a nucleic acid test (NAT) for detection of HCV ribonucleic acid ( i.e. , NAT for HCV RNA) at 2-6 months of age to facilitate early identification and linkage to care for children with perinatally acquired HCV infection. Untreated hepatitis C can lead to cirrhosis, liver cancer, and premature death and is caused by HCV, a blood-borne virus transmitted most often among adults through injection drug use in the United States...
March 13, 2024: Journal of Women's Health
https://read.qxmd.com/read/38473009/diagnosis-management-and-prognosis-of-cystic-fibrosis-related-liver-disease-in-children
#25
REVIEW
Dana-Teodora Anton-Păduraru, Alice Nicoleta Azoicăi, Felicia Trofin, Alina Mariela Murgu, Dana Elena Mîndru, Ana Simona Bocec, Codruța Olimpiada Iliescu Halițchi, Gabriela Rusu Zota, Diana Păduraru, Eduard Vasile Nastase
Cystic fibrosis (CF) is a multifaceted disorder predominantly investigated for its pulmonary manifestations, yet patients with CF also exhibit a spectrum of extrapulmonary manifestations, notably those involving the hepatobiliary system. The latter constitutes the third leading cause of morbidity and mortality in individuals with CF. Cystic fibrosis-related liver disease (CFLD), with an escalating prevalence, manifests diverse clinical presentations ranging from hepatomegaly to cirrhosis and hepatopulmonary syndrome...
March 3, 2024: Diagnostics
https://read.qxmd.com/read/38466273/cost-effectiveness-of-strategies-for-treatment-timing-for-perinatally-acquired-hepatitis-c-virus
#26
JOURNAL ARTICLE
Megan Rose Curtis, Rachel L Epstein, Pamela Pei, Benjamin P Linas, Andrea L Ciaranello
IMPORTANCE: Prevalence of chronic hepatitis C virus (HCV) infection among pregnant people is increasing in the US. HCV is transmitted vertically in 7% to 8% of births. Direct-acting antiviral (DAA) therapy was recently approved for children with HCV who are 3 years or older. The clinical and economic impacts of early DAA therapy for young children with HCV, compared with treating at older ages, are unknown. OBJECTIVE: To develop a state-transition model to project clinical and economic outcomes for children with perinatally acquired HCV to investigate the cost-effectiveness of treating at various ages...
March 11, 2024: JAMA Pediatrics
https://read.qxmd.com/read/38456192/clinical-spectrum-of-hereditary-tyrosinemia-type-1-in-a-cohort-of-pakistani-children
#27
JOURNAL ARTICLE
Sabeen Abid Khan, Misbah Fakih, Nida Taufiq, Afaaf Ahmerin, Asfand Bangash, Munir Iqbal Malik
BACKGROUND: Hereditary Tyrosinemia Type 1 (HT1), a rare autosomal recessive metabolic disorder, arises from fumarylacetoacetate (FAH) enzyme deficiency, resulting in toxic metabolite buildup. It manifests in acute, subacute, and chronic forms, with early diagnosis and Nitisinone treatment being vital. OBJECTIVES: The study aims to highlight the different clinical presentations of Hereditary Tyrosinemia type 1 in a cohort of Pakistani children. DESIGN: Retrospective observational study...
2024: Clinical Medicine Insights. Pediatrics
https://read.qxmd.com/read/38453980/the-deleterious-effects-of-sofosbuvir-and-ribavirin-antiviral-drugs-against-hepatitis-c-virus-on-different-body-systems-in-male-albino-rats-regarding-reproductive-hematological-biochemical-hepatic-and-renal-profiles-and-histopathological-changes
#28
JOURNAL ARTICLE
Rana A Ali, Eatemad A Awadalla, Yahia A Amin, Samer S Fouad, Maha Abd-El Baki Ahmed, Mohammed H Hassan, Emaad Abdel-Kahaar, Rehab H Abdel-Aziz
Sofosbuvir is one of the crucial drugs used in the treatment of chronic hepatitis C virus (HCV) in adults and children with compensated liver disease, including cirrhosis. It may be used alone or with other drugs. Ribavirin is an antiviral medication used to treat HCV infection. It is not effective when used alone and must be used in combination with other medications, such as sofosbuvir. This study pertains to a comprehensive assessment of the deleterious effects of sofosbuvir (an antiviral drug against chronic HCV) or sofosbuvir combined with ribavirin (an antiviral drug against RNA and DNA viruses) on several biological activities of the body, including hematological, hormonal, biochemical, histological, and immunohistochemical examinations during a long-standing period on male healthy rats...
March 7, 2024: Scientific Reports
https://read.qxmd.com/read/38453472/food-insecurity-is-a-risk-factor-for-metabolic-dysfunction-associated-steatotic-liver-disease-in-latinx-children
#29
JOURNAL ARTICLE
Sarah L Maxwell, Jennifer C Price, Emily R Perito, Philip Rosenthal, Janet M Wojcicki
INTRODUCTION: Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common chronic liver disease among US children. Studies have associated food insecurity with MASLD in adults, but there are few studies of pediatric MASLD, particularly in high-risk populations. We assessed the impact of household food insecurity at 4 years of age on MASLD in Latinx children. METHODS: Using a prospective cohort design, Latina mothers were recruited during pregnancy and followed with their children until early to mid-childhood...
March 7, 2024: Pediatric Obesity
https://read.qxmd.com/read/38447037/genotype-correlates-with-clinical-course-and-outcome-of-children-with-tight-junction-protein-2-tjp2-deficiency-related-cholestasis
#30
JOURNAL ARTICLE
Bikrant Bihari Lal, Seema Alam, Anupam Sibal, Karunesh Kumar, Somashekara Hosaagrahara Ramakrishna, Vaibhav Shah, Nirmala Dheivamani, Ashish Bavdekar, Aabha Nagral, Nishant Wadhwa, Arjun Maria, Aashay Shah, Ira Shah, Zahabiya Nalwalla, Pandey Snehavardhan, K P Srikanth, Subhash Gupta, Viswanathan M Sivaramakrishnan, Yogesh Waikar, Arya Suchismita, A Ashritha, Vikrant Sood, Rajeev Khanna
OBJECTIVES: The study aimed to describe the clinical course, outcomes, and analyze genotype-phenotype correlation in patients with tight junction protein 2 (TJP2) deficiency. METHODS: Data from all children with chronic cholestasis and either homozygous or compound heterozygous mutations in TJP2 were extracted and analyzed. The patients were categorized into three genotypes: TJP2-A (missense mutations on both alleles), TJP2-B (missense mutation on one allele and a predicted protein-truncating mutation (PPTM) on the other), and TJP2-C (PPTMs on both alleles)...
March 6, 2024: Hepatology: Official Journal of the American Association for the Study of Liver Diseases
https://read.qxmd.com/read/38433535/maternal-gestational-hypertension-smoking-and-pre-eclampsia-are-associated-with-metabolic-dysfunction-associated-fatty-liver-disease-in-overweight-offspring
#31
JOURNAL ARTICLE
Hanna de Ruyter, Linnea Aitokari, Siiri Lahti, Hanna Riekki, Heini Huhtala, Timo Lakka, Hannele Laivuori, Kalle Kurppa
INTRODUCTION: Due to a steep increase in obesity, metabolic dysfunction-associated fatty liver disease (MAFLD) has also become the most common chronic hepatic condition among children and adolescents. Various maternal and pregnancy-related factors have also been implicated in the development of MAFLD, but human studies remain scarce. MATERIAL AND METHODS: Comprehensive data of 460 overweight or obese children aged 2-16 years were collected and combined with data on selected maternal and pregnancy-related factors for a case-control study...
March 3, 2024: Acta Obstetricia et Gynecologica Scandinavica
https://read.qxmd.com/read/38430280/galectin-3-levels-in-children-with-cystic-fibrosis
#32
JOURNAL ARTICLE
Dilber Ademhan Tural, Nagehan Emiralioglu, Senay Akin, Didem Alboga, Beste Ozsezen, Halime Nayir Buyuksahin, Ismail Guzelkas, Merve Kasikci, Birce Sunman, Irem Gungor, Ebru Yalcin, Deniz Dogru, Nural Kiper, Ali Haydar Demirel, Ugur Ozcelik
Cystic fibrosis (CF) is a multisystemic disease in which airway obstruction, infection, and inflammation play a critical role in the pathogenesis and progression of CF lung disease. The carbohydrate-binding protein Galectin-3 is increased in several inflammatory and fibrotic diseases and has recently been forwarded as a biomarker in these diseases. We aimed to define the role of serum Galectin-3 in children with CF by comparison with healthy subjects. This is a cross-sectional, case-control study. 143 CF and 30 healthy subjects were enrolled in the study...
March 2, 2024: European Journal of Pediatrics
https://read.qxmd.com/read/38429139/aetiology-and-diagnostic-utility-of-serum-ascites-albumin-gradient-in-children-with-ascites
#33
JOURNAL ARTICLE
Srinivas Srinidhi Vadlapudi, Anshu Srivastava, Nidhi Saini, Moinak Sen Sarma, Ujjal Poddar, Surender Kumar Yachha
BACKGROUND: Ascites in children is multifactorial and serum ascites albumin gradient (SAAG) ≥1.1 helps differentiate portal hypertension (PHTN) related from non-PHTN ascites. AIMS: We evaluated the aetiology and diagnostic accuracy of SAAG in children with ascites. METHODS: Children with ascites were retrospectively evaluated. Etiological diagnosis was based on clinical presentation and investigations. All cases with ascitic fluid analysis and a definite diagnosis were included for calculating the utility of SAAG...
February 29, 2024: Digestive and Liver Disease
https://read.qxmd.com/read/38417945/hepatoblastoma-in-a-cirrhotic-child-with-alagille-syndrome
#34
JOURNAL ARTICLE
Sumit Agrawal, Bishnupriya Sahoo, Karunesh Kumar, Smita Malhotra, Anupam Sibal
Alagille syndrome (AGS) is a genetic disorder due to mutations in the JAGGED 1 or NOTCH 2 genes leading to multisystemic manifestations. Though these patients are at risk of developing various liver tumours, no cases of hepatoblastoma among young children with cirrhosis in AGS have been reported. We report a male toddler, with cirrhosis due to AGS who developed a hepatoblastoma. He underwent a liver transplant for decompensated chronic liver disease with marked pruritus, very high alpha-fetoprotein levels and malignant liver lesions on positron emission tomography CT...
February 27, 2024: BMJ Case Reports
https://read.qxmd.com/read/38402346/ruxolitinib-for-the-treatment-of-acute-and-chronic-graft-versus-host-disease-in-children-a-systematic-review-and-individual-patient-data-meta-analysis
#35
JOURNAL ARTICLE
Francesco Baccelli, Francesca Gottardi, Edoardo Muratore, Davide Leardini, Antonio Giacomo Grasso, Davide Gori, Tamara Belotti, Arcangelo Prete, Riccardo Masetti
Steroid-refractory graft-versus-host disease (SR-GvHD) represents a major complication of pediatric allogenic hematopoietic stem cell transplantation. Ruxolitinib, a selective JAK 1-2 inhibitor, showed promising results in the treatment of SR-GvHD in adult trial, including patients >12 years old. This systematic review aims to evaluate ruxolitinib use for SR-GvHD in the pediatric population. Among the 12 studies included, ruxolitinib administration presented slight differences. Overall response rate (ORR) ranged from 45% to 100% in both acute and chronic GvHD...
February 24, 2024: Bone Marrow Transplantation
https://read.qxmd.com/read/38386359/a-rank-based-approach-to-evaluate-a-surrogate-marker-in-a-small-sample-setting
#36
JOURNAL ARTICLE
Layla Parast, Tianxi Cai, Lu Tian
In clinical studies of chronic diseases, the effectiveness of an intervention is often assessed using "high cost" outcomes that require long-term patient follow-up and/or are invasive to obtain. While much progress has been made in the development of statistical methods to identify surrogate markers, that is, measurements that could replace such costly outcomes, they are generally not applicable to studies with a small sample size. These methods either rely on nonparametric smoothing which requires a relatively large sample size or rely on strict model assumptions that are unlikely to hold in practice and empirically difficult to verify with a small sample size...
January 29, 2024: Biometrics
https://read.qxmd.com/read/38385884/uk-guideline-on-the-transition-and-management-of-childhood-liver-diseases-in-adulthood
#37
REVIEW
Deepak Joshi, Jeremy Nayagam, Lisa Clay, Jenny Yerlett, Lee Claridge, Jemma Day, James Ferguson, Paul Mckie, Roshni Vara, Henry Pargeter, Rachel Lockyer, Rebecca Jones, Michael Heneghan, Marianne Samyn
INTRODUCTION: Improved outcomes of liver disease in childhood and young adulthood have resulted in an increasing number of young adults (YA) entering adult liver services. The adult hepatologist therefore requires a working knowledge in diseases that arise almost exclusively in children and their complications in adulthood. AIMS: To provide adult hepatologists with succinct guidelines on aspects of transitional care in YA relevant to key disease aetiologies encountered in clinical practice...
February 22, 2024: Alimentary Pharmacology & Therapeutics
https://read.qxmd.com/read/38385381/therapeutic-plasma-exchange-in-children-with-acute-and-acuteon-chronic-liver-failure-a-single-center-experience
#38
JOURNAL ARTICLE
Sadık Kaya, Neslihan Ekşi Bozbulut
OBJECTIVES: Acute liver failure is a life-threatening condition that may result in death if liver transplant is not performed. The aim of our study was to evaluate patients with acute liver failure or acute-on-chronic liver failure who were followed and treated with therapeutic plasma exchange in a pediatric intensive care unit until they achieved clinical recovery or underwent liver transplant. MATERIALS AND METHODS: In this retrospective, singlecenter study, we included patients with acute liver failure or acute-on-chronic liver failure who received therapeutic plasma exchange between April 2020 and December 2021...
January 2024: Experimental and Clinical Transplantation
https://read.qxmd.com/read/38376650/functional-cure-is-associated-with-younger-age-in-children-undergoing-antiviral-treatment-for-active-chronic-hepatitis-b
#39
JOURNAL ARTICLE
Min Zhang, Jing Li, Zhiqiang Xu, Peiyao Fan, Yi Dong, Fuchuan Wang, Yinjie Gao, Jianguo Yan, Lili Cao, Dong Ji, Danni Feng, Yanwei Zhong, Yang Zhang, Weiguo Hong, Chao Zhang, Fu-Sheng Wang
BACKGROUND AND AIMS: Functional cure is difficult to achieve using current antiviral therapies; moreover, limited data are available regarding treatment outcomes in children. This retrospective study aimed to assess the frequency of functional cure among children undergoing antiviral treatment for active chronic hepatitis B (CHB). METHODS: A total of 372 children aged 1-16 years, with active CHB were enrolled and underwent either nucleos(t)ide analog monotherapy or combination therapy with interferon-α (IFN-α) for 24-36 months...
February 20, 2024: Hepatology International
https://read.qxmd.com/read/38369891/espghan-recommendations-on-treatment-of-chronic-hepatitis-c-virus-infection-in-adolescents-and-children-including-those-living-in-resource-limited-settings
#40
JOURNAL ARTICLE
Giuseppe Indolfi, Regino P Gonzalez-Peralta, Maureen M Jonas, Manal Hamdy-El Sayed, Björn Fischler, Etienne Sokal, Stefan Wirth, Emanuele Nicastro
Hepatitis C virus (HCV) infection is a major cause of chronic liver disease worldwide, with more than three million viraemic adolescents and children. Treatment of adults with HCV infection and HCV-related liver disease has advanced considerably thanks to development and improvements in therapy. Direct-acting antiviral regimens are safe and effective. Three regimens with pangenotypic activity (glecaprevir/pibrentasvir, sofosbuvir/velpatasvir and sofosbuvir/velpatasvir/voxilaprevir) and three regimens with genotype-specific activity (sofosbuvir/ribavirin, sofosbuvir/ledipasvir and elbasvir/grazoprevir) have been approved with age-specific limitation for treatment of children with chronic hepatitis C by the European Medicines Agency and the United States Food and Drug Administration...
February 18, 2024: Journal of Pediatric Gastroenterology and Nutrition
keyword
keyword
102139
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.